NanO2 for Large Vessel Occlusion Stroke
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT05389748
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 300 participants
- Registry
-
NCT05389748
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05389748. Randomized; single masking; primary purpose treatment. Start 2023-04-01 (anticipated); primary completion 2025-04-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- NanO2 for Large Vessel Occlusion Stroke
- Acronym
- PROVEN
- Condition
- Ischemic Stroke
- Intervention (Other)
- Placebo
- Intervention (Biological)
- dodecafluoropentane emulsion (DDFPe)
- Lead sponsor
- NuvOx LLC
- Collaborator
- University of Arkansas
- Collaborator
- Stanford University
- Collaborator
- Washington Regional Medical Center
Record details
- Record id
cardio:ct-nct05389748- Content hash
268e33d309929a4b9afc87f3ceaba708760c3d186d71608b94a194576b975948